Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.
Products, services, technology
Small molecule amyloid pore inhibitors for the treatment of deadly degenerative diseases (in development).
- https://www.amporin.com/
- +41 78 749 49 36
- Send an email
- Kelvin Stott
Some insights
Amporin is developing novel treatments to stop and reverse the progression of deadly degenerative diseases that affect over 500 million people at a cost of USD 3 trillion per year.
Amporin is breaking the mold with a truly disruptive technology targeting a novel and unique mechanism of action.
Amporin's 3 cofounders each have over 20 years of industrial R&D leadership experience in CNS drug discovery and development.
Develop new drugs that could help millions of people with deadly debilitating diseases.
Help raise our profile to connect us with international partners and investors.
